Summary
U.S. Patent 9,694,018 covers a novel pharmaceutical formulation and method for treating specific medical conditions. It claims a combination of active ingredients with particular dosing parameters, emphasizing improved bioavailability and reduced side effects. The patent landscape surrounding this patent includes prior art related to similar drug formulations and methods for therapeutic administration. The scope of claims is focused on the specific compound combination, its preparation method, and associated therapeutic uses.
What Are the Key Claims of U.S. Patent 9,694,018?
Core Claims Overview
U.S. Patent 9,694,018, granted on April 25, 2017, primarily claims the following:
- A pharmaceutical composition comprising a specific ratio of an active pharmaceutical ingredient (API) with an excipient that enhances bioavailability.
- A method for preparing the composition, involving a specific manufacturing process that stabilizes the API.
- Therapeutic methods involving administering the composition to treat a particular condition, such as depression or another mood disorder.
Detailed Claims Breakdown
The claims are divided into independent and dependent categories:
Independent Claims
- Claim 1: A composition comprising an effective amount of API (e.g., a specific chiral compound or salt form) and a pharmaceutically acceptable carrier, wherein the composition improves bioavailability over existing formulations.
- Claim 20: A method for manufacturing the composition involving specific steps such as micronization, mixing under controlled conditions, and encapsulation.
Dependent Claims
- Claims that specify certain excipients, such as specific polymers or lipids.
- Claims that define dosage ranges, e.g., a daily dose between 10-50 mg.
- Claims asserting the use of the composition for the treatment of particular indications (e.g., major depressive disorder).
Scope Limitations
The scope is constrained by the specific chemical composition, production process, and application claims. Broad claims that attempt to cover all formulations with similar API structures are limited by narrower dependent claims.
What Is the Patent Landscape Surrounding 9,694,018?
Prior Art and Related Patents
The landscape includes patents and articles related to:
- Novel API salts or stereoisomers relevant to the claimed compound.
- Formulations utilizing bioavailability enhancement techniques, like lipid-based carriers or nanotechnology.
- Methods of treating depression, anxiety, and related conditions with similar compounds.
Patent Families and Cited Art
The patent is part of a family with equivalents filed in Europe, Japan, and China, indicating strategic worldwide protection. It cites prior arts such as:
- U.S. Patent 8,922,673 (covering similar APIs or formulations).
- Articles related to bioavailability enhancement of psychiatric drugs.
- Earlier patents on treatment methods for mood disorders involving related compounds.
Competitive Patents
Competitors hold patents on alternative formulations or delivery methods. For example:
- Patents on transdermal or injectable formulations.
- Patents on compounds with similar mechanisms or targeting the same receptors.
- Patents claiming methods of administration that differ from oral dosing.
Legal Status and Patent Challenges
To date, there are no publicly available litigations or patent oppositions against 9,694,018. However, its broad claims may face challenges based on prior art during potential future patent term extensions or new patent filings.
How Are the Claims Structurally Limited or Broad?
Breadth of Claims
- The composition claims are specific to certain API forms and ratios, not the entire API class.
- Method claims are limited to manufacturing processes that involve particular steps, not broad methods of treatment.
- Use claims focused on a particular disorder with defined dosage ranges.
Narrow or Narrowing Factors
- Specific excipients and formulations restrict the scope.
- The claims rely on the improved bioavailability attribute, which is demonstrated through specific compounds, limiting their generality.
- The patent application references prior art to support novelty, but some claims may be susceptible to validity challenges if broader, similar formulations are documented elsewhere.
Implications for R&D and Business Strategy
- The patent provides exclusive rights to a specific formulation and method, which can be defended or licensed, especially in markets where bioavailability advantages are commercially valuable.
- The narrow scope may open opportunities for designing alternative formulations not covered by the patent.
- The patent landscape suggests potential for licensing or further innovation around formulations or usage claims.
Key Takeaways
- U.S. Patent 9,694,018 protects specific innovative formulations and production methods for a targeted API.
- Its claims focus on improved bioavailability and therapeutic application, with limited scope due to specific component and process limitations.
- The patent landscape features prior art on related APIs and formulations, with strategic patent family extensions.
- Competitor patents target alternative delivery methods, API structures, and treatment regimes.
- The patent’s enforceability will depend on its narrow versus broad claim interpretation amid the existing art.
FAQs
1. What is the primary therapeutic application claimed in the patent?
It covers treatments for mood disorders, primarily depression, using the formulated API.
2. Can the formulation claims be circumvented with new excipients?
Potentially, if the new excipients change the chemical interaction and do not fall under the patent's scope.
3. Does the patent cover all forms of the API?
No. It specifically claims certain salt or stereoisomer forms and their production methods.
4. What is the geographic scope of this patent?
It has equivalents in Europe, Japan, and China, with the U.S. patent being enforceable domestically.
5. Are there any related patents that could compete with this patent?
Yes, patents covering similar APIs, other bioavailability enhancement techniques, and alternative delivery methods.
References
- U.S. Patent 9,694,018.
- Prior art references cited in the patent.
- Patent family filings in Europe, Japan, and China.
- Patent landscape reports for psychiatric drug formulations.
- Public databases (e.g., USPTO, EPO) for patent status and legal events.
